BioNTech SE Sponsored ADR $BNTX Shares Newly Bought by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. acquired a new stake in BioNTech SE Sponsored ADR (NASDAQ:BNTX) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 6,249 shares of the company’s stock, valued at approximately $614,000.

A number of other hedge funds have also added to or reduced their stakes in the stock. Headlands Technologies LLC bought a new stake in shares of BioNTech during the second quarter valued at approximately $2,520,000. Bank of America Corp DE grew its stake in BioNTech by 22.6% in the first quarter. Bank of America Corp DE now owns 903,029 shares of the company’s stock worth $80,261,000 after purchasing an additional 166,432 shares in the last quarter. Amundi grew its stake in BioNTech by 24.5% in the first quarter. Amundi now owns 129,513 shares of the company’s stock worth $11,511,000 after purchasing an additional 25,506 shares in the last quarter. Assenagon Asset Management S.A. grew its stake in BioNTech by 79.7% in the third quarter. Assenagon Asset Management S.A. now owns 760,675 shares of the company’s stock worth $74,774,000 after purchasing an additional 337,412 shares in the last quarter. Finally, Flossbach Von Storch SE purchased a new position in BioNTech during the 2nd quarter worth $207,142,000. 15.52% of the stock is currently owned by institutional investors.

BioNTech Stock Performance

NASDAQ BNTX opened at $87.51 on Monday. BioNTech SE Sponsored ADR has a 52 week low of $79.52 and a 52 week high of $124.00. The company has a 50 day moving average price of $94.66 and a 200 day moving average price of $96.70. The company has a quick ratio of 8.52, a current ratio of 8.55 and a debt-to-equity ratio of 0.01. The firm has a market cap of $22.13 billion, a PE ratio of -12.78 and a beta of 1.28.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on BNTX. Morgan Stanley decreased their target price on BioNTech from $114.00 to $106.00 and set an “overweight” rating for the company in a research report on Wednesday, November 4th. Canaccord Genuity Group cut their price target on BioNTech from $136.00 to $132.00 and set a “buy” rating on the stock in a research note on Wednesday, October 14th. Weiss Ratings restated a “sell (d-)” rating on shares of BioNTech in a report on Friday, October 2nd. Berenberg Bank set a $140.00 price objective on BioNTech in a report on Wednesday, September 16th. Finally, Citigroup lowered their price objective on shares of BioNTech from $130.00 to $125.00 and set a “buy” rating for the company in a research note on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $123.60.

Insiders Place Their Bets

In other BioNTech news, CEO Ugur Sahin sold 36,209 shares of BioNTech stock in a transaction on Friday, October 9th. The shares were sold at an average price of $95.37, for a total value of $3,453,252.33. Following the transaction, the chief executive officer directly owned 36,209 shares of the company’s stock, valued at approximately $3,453,252.33. The trade was a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 807,209 shares of company stock valued at $79,246,837 in the last three months. 19.20% of the stock is owned by company insiders.

About BioNTech

BioNTech SE is a biotechnology company based in Mainz, Germany. Founded in 2008, it develops medicines and vaccines, with a focus on immunotherapies for cancer and infectious diseases.

The company’s research uses technologies including messenger RNA (mRNA), antibodies, and cell-based therapies. Its best-known product is Comirnaty, an mRNA vaccine against COVID-19 developed and commercialized in partnership with Pfizer. BioNTech also has a broad oncology research and development portfolio.

BioNTech works with partners to develop and distribute products internationally.